Standard BioTools第四季度每股收益$(0.09)不及预期$(0.07),销售额$4672万超预期$4303万

财报速递2025-02-27
Standard BioTools (NASDAQ:LAB)报告第四季度每股亏损$(0.09),未达到分析师普遍预计的$(0.07),相差28.57%。 相比去年同期每股亏损$(0.25),这是64%的改善。 公司报告季度销售额为$4672万,超出分析师普遍预计的$4303万,超出8.56%。 相比去年同期$2819万的销售额,这增加了65.74%。

以上内容来自Benzinga Earnings专栏,原文如下:

Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 64 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $46.72 million which beat the analyst consensus estimate of $43.03 million by 8.56 percent. This is a 65.74 percent increase over sales of $28.19 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法